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Abstract Paediatric high grade glioma (pHGG) (World
Health Organisation astrocytoma grades III and IV)
remains poor prognosis tumours, with a median survival of
only 15 months following diagnosis. Current investigation
of anti-angiogenic strategies has focused on adult glio-
blastoma multiforme (GBM) with phase III trials targeting
vascular endothelial growth factor continuing. In this study
we investigated whether the degree of vascularity corre-
lated with prognosis in a large cohort of pHGG (n = 150)
and whether different vessel markers carried different
prognostic value. We found that CD105 (endoglin) had a
strongly significant association with poor prognosis on
multivariate analysis (p = \0.001). Supervised hierarchi-
cal clustering of genome wide gene expression data
identified 13 genes associated with differential degrees of
vascularity in the cohort. The novel angiogenesis-associ-
ated genes identified in this analysis (including MIPOL-1
and ENPP5) were validated by realtime polymerase chain
reaction. We also demonstrate that CD105 positive blood
vessels associate with CD133 positive tumour cells and
that a proportion of CD105 positive vessel cells demon-
strates co-positivity for CD133, suggesting that the recently
described phenomenon of vasculogenic mimicry occurs in
pHGG. Together, the data suggest that targeting angio-
genesis, and in particular CD105, is a valid therapeutic
strategy for pHGG.
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Introduction
In children high grade gliomas (HGG) (WHO astrocytoma
grade III and IV) represent around 10% of intracranial
neoplasms [14] and continue to have poor median survival
rates of 14 [43] to 18[4] months. Brain tumours are the
leading cause of cancer-related death in children,
accounting for 10,000 lost years of expected life per year in
the UK. Current multi-modal therapy of attempted gross
total surgical resection, followed by radical radiotherapy
and cytotoxic chemotherapy, can cause substantial mor-
bidities with limited survival benefits. HGG are highly
vascular tumours suggesting a potential novel therapeutic
approach to target angiogenesis, thereby controlling
tumour growth by disrupting the vascular network that
supplies and supports this process [37].
Current phase III trials in adult GBM are targeting the
pro-angiogenic ligand vascular endothelial growth factor
(VEGF) via monoclonal antibody or small molecule
inhibitor therapy [1]. Recent studies by our group and
others have demonstrated substantial molecular differences
between adult and paediatric HGG [35]. It is therefore
important to quantify whether angiogenesis has as critical a
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role in childhood tumours as in adults and whether variant
molecular pathways control the process.
Glioma vasculature formation occurs through at least
three distinct processes. Angiogenesis is the process of
generating new blood vessels from rerouting and remod-
elling of pre-existing vessels [37]. Vasculogenesis (blood
vessel arrangement) was classically considered as an
embryonic process, but has since been identified in tumours
as the de novo formation of primitive blood vessels by the
differentiation of circulating bone marrow-derived endo-
thelial progenitor cells [40]. In addition, the process of
vasculogenic mimicry [39] provides a contribution to
tumour vasculature [45] by trans-differentiation of glioma
cells into tumour-derived endothelial cells [42].
Among solid tumours, glioblastoma multiforme
displays the most angiogenic features and the highest
degree of vascular proliferation and endothelial cell
hyperplasia [7]. Malignant gliomas require angiogenesis
to establish a source of nutrients and oxygen and to
eliminate cellular waste products [16]. Studies have also
established that the tumour vasculature creates a protec-
tive ‘microvascular niche’, within which tumour-initiating
cells can resist therapy [8]. Angiogenesis is thus a key
pathologic event in HGG and necessary for the progres-
sion of a localised neoplasm to a highly aggressive
tumour. The molecular processes involved in the ‘angio-
genic switch’ are still being elucidated, with it remaining
unclear whether the same factors predominate in children
as in adults.
Conventional immunohistochemical measurement of
microvessel density as a proxy marker for angiogenic
activity has utilised markers of mature endothelial cells
such as CD31 (PECAM), CD34 or factor VIII. Variable
results have been achieved, both in HGG [28] and other
tumour types [38] with some groups finding strong corre-
lations with prognosis, but other centres finding no link to
outcome [6].
CD105 (cluster of differentiation molecule 105)
(endoglin) is a transmembrane homodimer protein of 180 kDa
which is characteristically found on endothelial (blood
vessel) walls [17]. It is a key component of the trans-
forming growth factor b (TGFb) receptor signalling
pathway, involved with both receptors 1 and 2 [15]. CD105
fulfils key roles in angiogenesis and vasculogenesis during
development (possibly through preventing apoptosis in
hypoxic endothelial cells [29]) and mice that are null for
the CD105 allele die due to aberrant yolk sac and cardiac
development. The autosomal dominant condition heredi-
tary haemorrhagic telangiectasia (Osler-Weber-Rendu
syndrome type 1) is associated with mutations in the
CD105 gene (located on chromosome 9) and thalidomide
has been proposed for this condition as a way of stimu-
lating vessel maturation [27].
As a marker for blood vessels CD105 is associated with
immature vessels, and some studies have suggested it could
be a marker that preferentially stains for novel angiogenic
vessels. It has also been proposed that CD105 is a marker
for mesenchymal stem cells [9]. In some tumour types it
has been correlated negatively with prognosis [50], but its
role in HGG (particularly in childhood) is not yet clear [2,
6, 19, 34, 47]. Because of its apparent specificity for
tumour-associated blood vessels, CD105 is also of interest
as a therapeutic target, with monoclonal antibody therapy
in early stage clinical trials [18].
Because of its association with developing blood ves-
sels, we hypothesised that CD105 may be a more
representative measure of angiogenic activity in pHGG
tissue, and that genetically characterising tumours with
differing levels of CD105 may identify novel genes
involved in paediatric angiogenesis. The micro-environ-
ment in immediate proximity to blood vessels has been
suggested as an area enriched for, and supportive of,
tumour initiating cells [10], such as those identified by
CD133 positivity. We therefore also postulated that, as
newly generated vasculature, CD105 positive vessels may
be especially crucial to this microvascular niche, and may
even be in part the product of tumour initiating cells (the
process of vasculogenic mimicry). Overall, we demonstrate
that CD105 is a superior prognostic marker compared to
other vasculature-associated molecules in pHGG, that
novel genes are associated with levels of angiogenic
activity in pHGG and that CD105 positive vessels associate
with CD133 positive tumour cells.
Materials and methods
Tumour samples
The tissue microarrays utilised in this paper were built
from 150 samples banked by the Children’s Cancer Leu-
kaemia Group (UK CCLG) through Nottingham Children’s
Brain Tumour Research Centre (www.CBTRC.org). All
samples were surgically collected ante-mortem at UK
paediatric neurosurgical centres and are from paediatric
high grade gliomas (both supratentorial and brainstem)
with diagnosis confirmed by central pathological review
(JL and Keith Robson). The cohort consisted of 102 chil-
dren diagnosed with GBM, 29 with anaplastic astrocytoma
(AA), 10 with HGG not otherwise specified, 8 with
anaplastic oligodendroglioma and 1 with anaplastic pleo-
morphic xanthoastrocytoma. Full consent and ethical
approval has been obtained for their use in this study, from
the UK Children’s Cancer and Leukaemia Group and local
ethical and Trent MREC approval (06/MRE04/86). A full
clinical dataset, including demographic and treatment
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details, is available for each of the samples in this cohort.
Three cores from representative regions of each tumour
were included on the tissue microarray.
The gene expression analysis utilised a cohort of 53 de
novo pHGG analysed by our group and collaborators as
detailed previously [35], with the array data publicly
available (GEO accession number GSE19578). All these
samples also underwent central pathological review. Six-
teen of these samples subjected to gene expression analysis
were included on the tissue microarrays.
Immunohistochemistry
Immunohistochemistry against the tissue microarrays
commenced with de-paraffinisation in ethanol and xylene,
followed by antigen retrieval in sodium citrate in a steamer
for 40 min (for Ki67, CD31, CD133 and VEGF). For
CD105, a proteinase K antigen retrieval method was uti-
lised. After deparaffinisation, sections were covered with
100 ll of proteinase K solution (Sigma-Aldrich UK)
(20 lg/ml). Specimens were then placed in a humidifica-
tion chamber and then warmed to 37C for 15 min in an
oven. Anti-KI 67 (Dako monoclonal mouse anti-human Ki
67 antigen, clone MiB-1), anti-CD31 (Dako monoclonal
mouse anti-human CD31, endothelial cell, clone JC70A),
anti-CD105 (Dako monoclonal mouse anti-endoglin,
SN6 h), and anti-VEGF (Dako monoclonal mouse anti-
human vascular endothelial growth factor, Clone VG1)
were all utilised at 1:50 concentration. Anti-KI 67 was
applied for 30 min, all other antibodies were applied for
1 h at room temperature. Secondary antibody (100 ll Dako
horse radish peroxidase conjugated rabbit anti-mouse) was
applied for 30 min at room temperature. Finally, 2 ll of
3,30-Diaminobenzidine chromogen in 98 ll of Dako REAL
substrate buffer was applied before haemotoxylin count-
erstaining and mounting. At least three TMA cores were
analysed for each tumour for each antibody, with the area
of strongest staining in each core being assessed. For Ki67,
scoring was performed by taking the most positive high
powered field for each core and counting the number of
positive nuclei as a percentage of the total number of nuclei
present. When assessing Ki67 staining in vessel wall cells,
all the blood vessels definitively identifiable as such in the
core were first selected. The number of cell nuclei in the
vessel wall staining positive for Ki67 were then counted as
a percentage of the total number of nuclei in the vessel
wall. Mitotic index was calculated by counting the number
of mitotic figures per high powered field for at least three
representative fields for each tumour. For CD31 and
CD105, the total number of positive vessels per TMA core
were counted. On whole sections of 12 paediatric HGG,
defined areas of geographic necrosis were selected and the
distance to the 10 nearest blood vessels staining positive
for CD31 or CD105 was measured. For VEGF, as a cyto-
plasmic stain, scoring was undertaken by assessing the
approximate percentage of cells staining positive (- = 0–1%,
? = 1–5%, ?? = 5–20%, ??? = [20%).
Immunofluorescence
Deparaffinisation was undertaken with ethanol and xylene
washes, followed by antigen retrieval in 1 mM ethylene-
diaminetetraacetic acid (EDTA) buffer, adjusted to pH 8.0,
heated in a steamer for 40 min. Blocking solution was
applied (10% normal goat serum (NGS), 0.1% Triton
X-100 in PBS, 1% bovine serum albumin) for 1 h in the
dark at room temperature. Primary antibodies (CD31 and
CD105 as above; CD133 Abcam rabbit polyclonal) were
applied overnight in the dark at 4C. Secondary antibody
combinations of Alexa488-conjugated goat anti-rabbit
(1:200) and Alexa555-conjugated goat anti-mouse (1:200),
diluted in 2% NGS antibody diluent were then applied for
2 h in the dark at room temperature. Vectashield with
DAPI mounting medium (CA94010, Vector Laboratories,
Peterborough) was used. Images were taken using a Nikon
ECLIPSE 90i light microscope fitted with a Hamamatsu
OCRA-ER camera, using three fluorescent light filters;
DAPI (excitation 340–380 nm), FITC (Ex 405–495 nm)
and Texas-red (Ex 540–580 nm) and Volocity 5.0 imaging
software. On average three images were taken per core
wherever positive staining for CD31 or CD105 blood
vessels was visible. Measurements were performed using
the line measurement tool in Volocity; the distance
between the centres of the nuclei for CD133? cells was
measured to the edge of the closest CD31? or CD105?
blood vessel (see online resource 1). This was also per-
formed for all CD133- cells in each image.
Gene expression validation by quantitative real-time
polymerase chain reaction
As previously detailed [35], analysis was conducted using
the Affymetrix U133 plus2 platform and array data have
been deposited at the Gene Expression Omnibus Web site
(http://www.ncbi.nlm.nih.gov/geo/, accession No.GSE19578).
RNA was isolated from representative tumour speci-
mens using the mirVana RNA isolation kit (Ambion,
Austin, Tx). cDNA was produced with the RT2 First Strand
Kit (Qiagen). Target genes identified on array analysis
were validated with quantitative real-time PCR using a
CFX96 realtime system (BioRad laboratories, Herts, UK).
SYBR Green Supermix (Quanta Biosciences Gaithersburg,
MD) was used with the following primer sequences (50–30)
CD109—GAAGCTGTCCTCCTGTGACC; TCACAGCC
AAAGTTCCATAAAG; ENPP5—TTGCACCCATGT
CACAGAAT; CACTTATCACCTTCTTCTTCTCTCA
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MIPOL1—TGGTCATGCATGGAGTCTTG; ACTTACC
TGCACCTCCCAGA GAPDH—CTGACTTCAACAGC
GACA; TGCTGTAGCCAAATTCGTTG. The following
programme was used: initial activation at 95C for 10 min,
followed by 40 cycles of denaturation at 95C for 15 s,
annealing at 59C for 30 s and extension at 72C for 30 s
followed by fluorescence read. Primer efficiency was cal-
culated and the expression of each gene in low and high
vascularity tumours calculated relative to normal adult
brain RNA (FirstChoice, Ambion) using the modified Pfaffl
equation R = Etarget DCT (CT target gene control-CT
target gene sample)/Econtrol DCT (CT control gene con-
trol-CT control gene sample) with GAPDH as the control
gene.
Statistical analysis
Analysis was performed using SPSS 16 with comparison
between groups undertaken using unpaired two-tailed
T test. Survival analysis was performed using a Cox
regression multivariate model and Kaplan–Meier plots
(log-rank) for discrete groups. Array analysis was per-
formed using Genespring software (Agilent, UK) with
multiple unpaired T tests between groups and Benjamini–
Hochberg multiple test correction applied throughout.
P values of less than 0.05 were considered significant.
Results
Tumour cohort
The tumour cohort consisted of 150 pHGG with diagnosis
confirmed by central pathological review, ranging in age
(at diagnosis) from 2 days to 21 years, with a mean age of
7 years and 10 months. The cohort consisted of 88 males,
54 females and 8 cases where sex was not recorded, a male
to female ratio of 1.6:1. Further details of the cohort have
been previously published [41]. One hundred and thirty-six
cases were obtained at first surgery and fourteen of the
cases were obtained from surgery at first recurrence. Six of
the children had survived previous (haematological)
malignancies. Overall survival was also in line with other
published series, with a 5-year-survival of 20% and median
survival of 15 months from diagnosis. Survival tended to
be extended with a diagnosis of AA compared to GBM
(median 18 vs. 12 months, respectively, though p =
0.065).
Immunohistochemistry
Ki67 staining data were acquired for 127 tumours with
survival data available for 100 patients (Fig. 1). For
individual tumour cores the proliferation index ranged
from 0 to 52%. When averaged over multiple cores for
each tumour, proliferation index ranged from 0 to 29.3%
with a mean of 685 cells counted per tumour. Heteroge-
neity was seen within individual tumours, with some cores
containing relatively high numbers of proliferating cells
and other cores appearing relatively quiescent. No corre-
lation could be demonstrated between overall proliferation
index and length of overall survival (p = 0.880) (Fig. 1).
When proliferation index was calculated specifically for
cells in perivascular areas there was a significant correla-
tion with overall patient survival (p = 0.012 Cox
univariate) (see supplementary resource 4). Mitotic index
across the wider tumour also had a significant correlation
with survival on univariate analysis (p = 0.048).
CD31 immunohistochemistry data were available for
123 tumours, with survival data available for 97 patients.
Mean number of positive staining vessels per core ranged
from 0 to 69 vessels/core with an overall mean of 7.6
vessels/core. Mean number of vessels/core averaged over
multiple cores for each individual tumour ranged from 0 to
48.5 vessels/core. For Kaplan–Meier purposes, tumours
were split into groups of mean vessels/core less than 5,
5–10, and greater than 10, giving 55, 37 and 31 tumours in
each group, respectively. This split was utilised as no
previous studies have used objective criteria and it gave
three roughly equal groups of samples.
There was no significant relationship between CD31
microvessel density (MVD CD31) and survival (p = 0.075
Cox regression). The data were then re-analysed with very
short-term survivors removed from the analysis (patients
who died less than 1-month post-surgery, n = 6) whose
short survival may have been determined by surgical
complications rather than tumour biology. There was now a
significant relationship between MVD CD31 and survival
(p = 0.008 hazard ratio = 0.934 Cox regression) with
patients tending to survive longer if their tumour had a
higher density of CD31 positive vessels (Fig. 1). There was
no significant difference in levels of CD31 staining
between GBM and AA (mean 7.1 vs. 8.6 vessels/core,
respectively; p = 0.265 T test).
Immunohistochemical staining for CD105 was achieved
for 118 tumours, with survival data available for 95 of
these patients. Vessels staining positive for CD105 tended
to be smaller and less mature in appearance (with higher
levels of Ki67 positive cells and less pericyte/smooth
muscle coverage) than vessels staining positive for CD31.
It was also noticeable that some structures that histologi-
cally appeared as blood vessels did not stain positive for
CD105. For individual tumours mean number of positively
stained vessels ranged from 0 to 36 vessels/core, with
single cores ranging from 0 to 59 vessels/core. Tumours
were grouped into three levels of microvessel density for
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Kaplan–Meier analysis—those with less than 3 vessels/
core (low), those with 3–8 (medium) and those with more
than 8 vessels/core (high). As with CD31 IHC, no previous
papers have used objective scoring systems, so the group-
ings are based on creating three groups of equal sample
numbers.
There was a highly significant relationship between
microvessel density as defined by CD105 immunostaining
(MVD CD105) and survival (Fig. 2). The greater the level of
MVD CD105, the worse a patient’s survival was likely to be
(p = 0.001 Cox regression, with hazard ratio of 1.05). All
long-term survivors ([8 years), for whom data were avail-
able, were in the lowest group of MVD CD105 (\3 vessels/
core). This relationship was identical on log rank testing by
groups (p = \0.001) and if the short-term survivors were
removed as for the CD31 analysis. The same relationship
was also found using the individual peak core count for each
tumour. There was a weak correlation between the peak
CD31 and CD105 values for each tumour (p = 0.022
Spearman) but not the mean values. There was no relation-
ship between mitotic index and microvessel density and the
levels of CD105 staining were the same in GBM and AA (8.0
vessels/core and 6.4 vessels/core, respectively; p = 0.445
T test). There was a significantly shorter mean distance
between areas of necrosis and CD105 positive vessels
(121.9 lm) than between areas of necrosis and CD31 posi-
tive vessels (193.1 lm) (p = 0.001 T test).
VEGF immunohistochemistry data were available for 102
tumours, with survival data available for 79 of these patients.
VEGF staining was variable with some cores being strongly
positive and some completely negative. Even with a single
core, expression could vary significantly, with VEGF
Fig. 1 a Paediatric glioblastoma exhibiting typical level of Ki67
staining (brown nuclei positive for MiB-1). b Mature blood vessel in
resected pHGG demonstrating positive endothelial staining for CD31
(brown lining of central lumen). c pHGG demonstrating high levels of
immature small blood vessels staining positive for CD105 (brown
structures). d, e, f Kaplan–Meier survival plots for Ki67, CD31 and
CD105 levels, respectively (All scale bars 25 lm)
Fig. 2 Immunohistochemistry for VEGF in the peri-ischaemic zone
(positive staining brown) demonstrating viable peripheral tumour
(asterisk) and central necrotic tumour core (hash) (scale bar 75 lm)
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positivity highest at the interface between necrotic and viable
regions of cells (Fig. 2). 58 tumours had some degree of
VEGF positivity. There was, however, no discernible rela-
tionship between extent of VEGF positivity and survival, age
or any other variable (for survival, p = 0.818 Cox
regression).
When multivariate analysis was performed for the 75
cases (Table 1) where information was available on all
variables included in the model (age, sex, histological
diagnosis, primary/recurrence, extent of surgery, adminis-
tration of chemo/radiotherapy, mitotic index, MVD CD31,
MVD CD105 and presence of VEGF) the significant
variables affecting survival were MVD CD31 and MVD
CD105 (p = 0.005 and \0.001, respectively), extent of
surgery and administration of radiotherapy. The effect of
MVD CD105 was slightly enhanced with hazard ratio
increased to 1.084. The effect of MVD CD31 also achieved
significance with an increased value correlating with
improved survival chances (hazard ratio = 0.891). There
was no significant association between age and any of the
other factors studied.
Gene expression
Gene expression analysis supervised on the basis of
microvessel density was possible for 16 of the tissue
microarray tumours that had been included in the gene
expression cohort previously published [35]. The data from
these 16 samples were uploaded into the Genespring
analysis software. Quality control analysis for these sam-
ples was satisfactory with all quality control metrics
passed. When multiple T testing with multiple test cor-
rection was performed, analysing the difference between
samples on the basis of MVD CD31 no significant genetic
differences were found. However, when the samples were
analysed on the basis of MVD CD105, 13 genes were
found to be significantly differentially expressed between
samples in the low (\3 vessels/core) group and tumours in
the medium and high groups (Table 2). Supervised hier-
archical clustering was performed on the samples using the
gene list with the results showing clear differences in
expression profiles and the tumours of low MVD CD105
all clustering together in the block on the right of the
cluster tree (online resource 2).
The genes that have been highlighted by this analysis
include mirror image polydactyly-1 (MIPOL1), a candidate
tumour suppressor gene and ENPP5 (a closely-related
molecule to ENPP2 (autotaxin)). In view of their known
tumour-related function these genes were selected for
validation of the gene expression array data. On rtPCR
significant differences in expression level relative to control
(adult normal brain RNA) were confirmed for MIPOL-1 and
ENPP5 (online resource 3).
Immunofluorescence
The proximity of CD133? and CD133- cells to the closest
CD31? blood vessel was compared by immunofluores-
cence (Fig. 3) across 20 tumours, measuring 5,617 cells
total. CD133? cells were found to be significantly closer,
on average, to CD31? vessels than CD133- cells, by 5.83
(p \ 0.001, 95% confidence interval 8.34–7.08 lm). 21
tumours were analysed from the co-staining of CD133 and
CD105, with 9,525 cells measured. On average, CD133?
cells were also significantly closer than CD133- cells to
CD105? blood vessels, by 15.14 lm (p \ 0.001, 95%
confidence interval 14.89–16.07 lm), with the differences
between CD133± cells greater for CD105 vessels than
CD31 vessels (p = \0.001) (Table 3).
There was no significant difference between the mean
distance from CD133? cells to CD31 vessels or CD105
vessels (41.0 vs. 40.8 lm, respectively, p [ 0.05 one way
ANOVA for 4 samples, Tukey HSD post hoc test).
CD133- cells were significantly further away from
CD31? vessels than CD105? vessels. The basis for the
increased differential for CD133± for CD105 vessels
Table 1 Multivariate Cox
regression survival model for
Paediatric High Grade Glioma
Variables significantly
associated with survival in bold
P value Exp (B) 95% Confidence interval for Exp (B)
Lower Upper
Age 0.460 1.002 0.996 1.008
Sex 0.082 0.559 0.291 1.077
VEGF status 0.191 1.285 0.882 1.872
MVD CD31 0.001 0.891 0.831 0.956
MVD CD105 <0.001 1.084 1.042 1.129
Chemotherapy 0.461 0.766 0.377 1.556
Radiotherapy 0.007 2.880 1.340 6.192
Resection status 0.001
Gross total vs. biopsy 0.011 2.783 1.262 6.137
Partial vs. biopsy 0.363 1.456 0.306 1.543
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therefore seems to be an increased separation of CD133-
cells from the blood vessel rather than increased proximity
of CD133? cells.
To investigate whether the proximity of CD133? cells to
CD105? vessels was affected by the patient’s age, patients
who were over 36-month-old at the time of diagnosis were
compared with those 36 months or under. In the[36-month-
group, CD133? cells were on average,*0.43 lm closer to
CD105? blood vessels than CD31? vessels, however, the
result was not statistically significant (p = 0.29). In contrast,
CD133? cells were significantly closer to CD31? blood
vessels in the 36 months or under group (by 4.73 lm,
p \ 0.001, 95% CI 5.56–3.90 lm). An increased proportion
of CD133? cells in an individual’s tumour showed a trend
towards correlation with decreased survival but did not
achieve statistical significance (p = 0.107 Cox regression).
To determine if the tumour type correlated with the
distance of CD133? cells from CD31? and CD105?
blood vessels, measurements for patients with GBM and
AA were analysed separately. The average proportion of
CD133? cells in GBM tumours (42.56%) was significantly
greater than AA tumours (24.62%) (p = \0.001). Com-
pared to AA, CD133? cells in GBM were significantly
closer to both CD31? blood vessels (by 4.96 lm
p \ 0.001, 95% CI 6.95–2.97 lm) and CD105? blood
vessels (by 9.22 lm p \ 0.001, 95% CI 11.62–6.82 lm).
There was no significant association (p = 0.107) found
between survival and proportion of CD133 expression
though patient numbers were small.
The co-staining demonstrated cells that were positive for
both CD133 (neural stem cell marker) and also for CD105
(endothelial marker) (Fig. 3). Up to 20% of vessel cells in
some tumours demonstrated this co-staining.
Discussion
CD105 has been suggested as a marker for angiogenic
blood vessels in both CNS and other cancers [17]. Our
study demonstrates a clear association between the number
of blood vessels staining positive for CD105 (a subset of
the total number of vessels) and the overall survival of
patients with pHGG. This association is present despite the
variety of treatments these patients underwent (biopsy
versus resective surgery; radiotherapy; various forms of
chemotherapy).
There are several possible explanations for the link
between CD105 and survival. When a tumour outgrows its
blood supply, ischaemia and necrosis result, leading to
generation of angiogenic mediators and the recruitment of
new blood vessels and epithelial precursor cells. This new
blood vessel network may then fuel further tumour growth
by supplying increased quantities of oxygen and other
necessary metabolites, leading to brain invasion and hence
worsened prognosis.
Many of the tumour-specific new vessels are small and
highly abnormal in morphology. The lumen is often small
such that the amount of blood carried by these vessels is
minimal, although there can be many vessels. A second
explanation for the association between the number of
novel vessels and tumour behaviour is that the vessel
architecture provides a microenvironment that is support-
ive of a subset of tumour cells (putative stem-like cells)
that provide resistance to radiotherapy or chemotherapy
[8]. This stem-like population is known to favour being in
close association with vessels and it is recognised that
tumour xenografts grow faster if co-grafted with endothe-
lial cells [49]. The co-existence of endothelial cells within
Table 2 Genes significantly differentially expressed between tumours with high and low CD105 microvessel density
Probe Set ID Chromosome Gene Gene ID Corrected
p value
P value Regulation
(high to low
vascularity)
FC
absolute
203931_s_at chr17q25.3 Mitochondrial ribosomal protein L12 MRPL12 0.0469 8.55E - 06 Down 1.34
205008_s_at chr15q25.1 Calcium and integrin binding family member 2 CIB2 0.0469 1.42E - 05 Down 1.62
211086_x_at chr4 q33 NIMA (never in mitosis gene a)-related kinase 1 NEK1 0.0469 7.15E - 06 Down 1.64
212787_at chr14q24.3 YLP motif containing 1 YLPM1 0.0469 8.13E - 06 Down 1.34
215210_s_at chr1p31.1 Dihydrolipoamide S-succinyltransferase DLST 0.0469 1.71E - 05 Down 1.31
227803_at chr6p12.3 Ectonucleotide pyrophosphatase/phosphodiesterase 5 ENPP5 0.0469 1.07E - 05 Down 9.25
229900_at chr6 q13 CD109 molecule CD109 0.0469 1.66E - 05 Down 1.91
233608_at chr3p24.1 CDNA FLJ11929 fis, clone HEMBB1000434 0.0469 3.79E - 06 Up 2.31
235570_at chr3 p24.1 CDNA FLJ36544 fis, clone TRACH2006378 0.0131 2.39E - 07 Up 2.75
240732_at chr6q27 Transcribed locus 0.0469 1.57E - 05 Down 1.15
244246_at chr14q21.1 Mirror-image polydactyly 1 MIPOL1 0.0274 1.00E - 06 Down 2.36
244836_at chr6q24.2 Transcribed locus 0.0469 7.29E - 06 Up 1.21
1565877_at chr6p22.3 Full length insert cDNA clone YP86C01 0.0469 1.15E - 05 Up 1.21
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Fig. 3 Co-immunofluorescence staining (blue nuclear DAPI stain-
ing): a CD105 (red) with CD133 (green) in an anaplastic
astrocytoma, b CD105 (red) with CD133 (green) in a glioblastoma
multiforme, c CD31 (red) with CD133 (green) in a glioblastoma
multiforme, d CD105 and CD133 demonstrating co-staining of
individual cells in vessel wall (arrowed) in a glioblastoma (scale bars
all 25 lm). e Control sections of human tonsil demonstrating negative
(ei) and positive (eii) controls for CD105 (red) and CD133 (green)
and negative (eiii) and positive (eiv) controls for CD31 (red) and
CD133 (green)
Table 3 Results comparing proximity of CD133± cells to CD31? and CD105? blood vessels and the difference between CD133± cells for
each vessel type
No. of cells Mean distance from vessel (lm) Significance of mean difference
Mean Mean difference P value
CD31? blood vessels CD133? 2,326 41.04 5.83 \0.001
CD133- 3,291 46.87
CD105? blood vessels CD133? 4,387 40.81 -15.14 \0.001
CD133- 5,138 55.95
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a tumour may provide a favourable scaffold to which the
glioma cells can attach, facilitating tumour growth via
more favourable cell–cell interactions.
A third possible mechanism is also linked to the cancer
stem cell hypothesis. CD105 is well recognised as a marker
for mesenchymal stem cells [9]. Some high grade gliomas
demonstrate mesenchymal features with a subset of glio-
blastoma featuring frank sarcomatous de-differentiation as
seen in gliosarcoma [31]. Some of the structures staining
positive for CD105 could potentially be mesenchymal
stem-like cells invading the brain parenchyma in response
to chemotactic cues from the tumour and hypoxia.
Recruitment of stem-like cells could lead to increased
vessel growth, paracrine stimulation of tumour growth or
further creation of a favourable microenvironment. It may
even be that aggressive HGG de-differentiate to the point
where they can re-acquire mesenchymal characteristics that
are not normally displayed on central nervous system cells.
Recent work has demonstrated the existence of this phe-
nomenon in adult HGG (termed vasculogenic mimicry)
[39, 42, 45]; our work provides evidence that this phe-
nomenon may also exist in pHGG.
There was a weak positive correlation between MVD
CD31 and overall survival once very short-term survivors
were removed from the analysis. This could be explained
by inclusion of normal brain parenchymal vessels into the
tumour and thus into the surgical specimen. In this case the
vessels could be a sign that the tumour is still at an early
stage of spread through the brain and that normal tissue
continues to survive within the tumour. At a later stage of
tumour growth the ischaemic conditions generated by the
cancer would lead to death of the normal tissue and
selection for hypoxia-resistant tumour cells, along with
tumour-induced CD105 positive blood vessels.
An alternative explanation is that the vessels staining
positive for CD31 are indeed formed as part of tumour
growth and are not simply bystander vessels incorporated
into the tumour as it invade surrounding brain. In this case
the slight survival benefit may be explained due to the level
of vessel maturity. Tumours that are more differentiated
may in turn produce vessels that are better differentiated
and will thus likely display higher levels of the mature
vessel wall marker CD31. Tumours with higher levels of
mature cells and less anaplasia will be more likely to have
a better prognosis as they may grow more slowly and
invade less extensively into surrounding brain. Alterna-
tively, CD31 positive vessels may be more efficient in
oxygenating the tumour parenchyma due to their greater
maturity and increased diameter. The improved tissue
oxygenation would then result in a decreased drive for
tumour cells to migrate out of hypoxic areas and invade
surrounding brain. Improved tumour oxygenation could
also potentially have other effects such as fuelling higher
tumour cell metabolism and turnover, or by influencing the
level of stem-like behaviour shown by tumour cells.
The lack of significant correlation between clinical
factors, MiB-1 and VEGF may also have various expla-
nations. One might expect mitotic index to correlate well
with prognosis as faster growing tumours should logically
lead to shorter survival, and indeed this has been found to
be the case in some CNS tumour types [44]. It is clear that
in paediatric HGG in this study, expression of MiB-1 is
highly variable across individual tumours. Certain patches
of cells within an otherwise bland field may have a high
mitotic rate, but the overall average across the count may
be low.
It may be that the sampling carried out in this study was
simply not extensive enough to accurately gauge the true
proliferation rate for each tumour and negative Ki67
staining may not necessarily imply quiescence, just that
negative cells have not been stained at the particular phase
of mitosis when the target protein is present. There is also
an issue with the scoring system as to how one incorporates
a small area of highly active tissue which may be the most
prognostically significant area into the overall assessment
of a tumour which may have large areas of less prolifera-
tive tissue. By contrast, scoring proliferation by counting
mitotic figures across multiple high powered fields showed
a significant relationship with survival, suggesting that rate
of cellular proliferation has an important influence on the
behaviour of these tumours. The interesting finding that
proliferation index in the perivascular population is sig-
nificantly correlated with survival supports the idea that it
is the proliferation rate of sub-populations within the
tumour rather than the total cell proliferation that is critical.
Tumours with increased perivascular proliferation may
have the capacity to increase their nutrient supply more
quickly than tumours with slower rates of blood vessel
growth. This increased proliferation could also be gener-
ating favourable microvascular niche environments at a
faster rate, thus enhancing tumour growth and possibly
promoting the stem-like fraction of cancer cells. Indeed, it
may even be that the proliferative cells identified in the
vessel walls are tumour cells undergoing a vasculogenic
mimicry type process. It is worth noting that proliferation
index is not currently part of the WHO grading criteria for
astrocytomas because of the difficulties in obtaining a
consistent inter-observer value for individual tumours.
VEGF is also locally and specifically expressed at the
hypoxic/normoxic interface where ischaemic conditions
trigger the angiogenic switch. Even within a single core, a
band of expression could often be seen with low levels on
either side of VEGF staining in the necrotic core and in the
viable periphery. It again seems that results for VEGF are
likely to be highly dependent on the precise location within
the tumour from where the sample came. In some tumours
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this region of maximal expression will not be visualised as
the specimen cores will have been extracted from other
regions of the tumour. Equally, on molecular biological
studies, only a small part of the tumour is analysed and
molecular differences may well exist within different
regions of the same tumour as well as between different
patients’ tumours.
The list of genes showing varying levels of expression
between tumours with high and low microvessel density as
measured by CD105 immunohistochemistry shows several
candidate genes of potential interest. Mirror image poly-
dactyly 1 (MIPOL1) is located on 14q and was initially
identified in a patient with this deformity [26], although the
mechanism of its action has not been identified. It is known to
be active in CNS development as loss of this gene can also
give rise to craniofacial defects and agenesis of the corpus
callosum [25]. MIPOL1 was implicated as a putative tumour
suppressor gene in nasopharyngeal carcinoma (NPC), where
chromosome 14 loss (including the MIPOL1 locus) is com-
mon [12]. Re-expression of MIPOL1 in NPC cell lines
greatly reduced their ability to proliferate or form tumours in
xenograft experiments. In our study MIPOL1 was found to be
2.4-fold downregulated in the higher vascularity tumours.
MIPOL1 protein is located in the nucleus and seems to exert
its effects by up regulating expression of p27 (WAF1/CIP1)
and p21 (KIP1), which are also implicated as angiogenic
markers in other malignancies.
Another gene of interest highlighted by this analysis is
CD109 (chromosome 6), a cell surface antigen which was
initially studied in CD34 positive acute myeloid leukaemia
cell lines, but has subsequently been found to be expressed
on a variety of haematopoietic cells and endothelial
structures [33]. It has also been implicated as a marker for a
subset of mesenchymal stem cells. Its function seems to be
negatively regulate TGFb signalling by direct action on the
receptor. Post-translational processing of the molecule into
smaller fragments seems to be necessary for the utilisation
of the TGFb signalling pathway by neoplastic cells [20]. It
has been implicated in breast cancer [23] (where RNAi
knockdown of CD109 suppressed malignant growth and
CD109 shed from the cell surface has a pro-growth func-
tion), squamous cell carcinoma of the oral cavity [21] and
is upregulated in various tumour cell lines including GBM
cell lines [22]. In our project CD109 was found to have a
1.99 fold change between high and low vascularity
tumours.
ENPP5 was highly differentially expressed (9.29 fold
change between groups). This molecule has not been
widely studied but the closely-related molecule ENPP2
(autotaxin) has been widely implicated in neoplasia and is
the focus of considerable efforts to develop small molecule
inhibitors [30]. It produces lysophosphatidic acid, a known
stimulant for cell proliferation, survival and invasive
behaviour. Other genes implicated in our study include
MRPL12, a downstream target of the REIC/Dkk3 tumour
suppressor in prostate cancer [11], CIB2 (a potential stress
response protein linking to apoptotic pathways) [48], NEK1
(down regulation of which may worsen the ability of the
cell to repair DNA damage) [36] and DLST (a component
of the respiratory chain). These genes will be further
investigated in novel three dimensional cell culture models
of angiogenesis we are currently developing.
This study also investigated whether cells marked with
the putative stem cell marker, CD133, were found in closer
proximity to the glioma vasculature than CD133- cells.
The results indicated that CD133? cells were found sig-
nificantly closer to both CD105? and CD31? blood
vessels than CD133- cells; this result is consistent with
other studies which have shown that glioma cells
expressing other stem cell markers, such as Nestin, were
located closer to brain tumour vessels than Nestin negative
cells [8, 13, 46]. The relatively high rates of CD133 posi-
tivity reported in our study may be related to the elevated
levels of stem-like cells found in the developing brain
compared to the adult brain. We also specifically selected
the peri-vascular areas as the focus for this study rather
than examining the tumour as a whole. Several groups have
reported that the peri-vascular niche is an area enriched for
stem-like cells [8] and by focusing on this area, one might
expect our rates of CD133 positivity to be higher than other
groups which assess the rate of positivity across the tumour
in its entirety.
It was observed that the difference of the proximity of
CD133? cells/CD133- cells to CD105? vessels was
greater than that to CD31? blood vessels. Furthermore,
when comparing GBM and AA tumour samples, CD133?
cells were found significantly closer to CD105? blood
vessels in GBM than in AA, but this difference between
GBM and AA was much less for CD31? blood vessels.
This suggests that CD105? vessels may have a more
important role than CD31? vessels in the vascular
microenvironment for stem-like cells, especially in grade
IV tumours. This could be related to the presence of
necrosis in the grade IV tumours and the greater proximity
of CD105 positive vessels to necrosis (compared to CD31
positive vessels) suggesting a role for CD105 in hypoxic
areas.
An interesting finding was that the average proportion of
total cells counted that were CD133? cells in GBM which
was greater than in AA. This may be associated with the
higher histological grading of GBM, thus supporting
studies that suggest CD133 expression can be used as a
prognostic factor [3] though CD133 did not achieve prog-
nostic significance in our study. It is possible that not all of
the CD133? cells counted will have been glioma CSC’s
with positive staining also depending upon the oxygen
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concentration and expression of the glycosylated AC133
epitope at different stages of the cell cycle [5, 24, 32].
Some CD31 and CD105 endothelial cells co-expressed
CD133, as part of the vessel wall or as single cells. CSC’s
in GBM tumours are suggested to be able to produce dif-
ferentiated neoplastic endothelial cells, forming part of the
hyperplastic GBM vasculature [39]. Our work suggests that
this phenomenon may also exist in paediatric HGG and
contributes to the development of tumour-associated vas-
culature in children.
This study demonstrates that CD105 positive vessels
have a significant role in the biology of pHGG and exert an
influence over prognosis even in a heterogeneously treated
cohort. Expression of different levels of CD105 by tumours
is associated with wider changes in gene expression,
allowing the identification of novel genes not previously
implicated in CNS tumour angiogenesis. One possible
explanation for the prognostic influence of CD105 is
through its role in developing the microvascular niche in
which stem-like cancer cells preferentially inhabit. Our
data provide evidence that this supportive micro-environ-
ment may be preferentially found in the proximity of
CD105 positive vessels as opposed to blood vessels stained
by other endothelial markers. This suggests that CD105 or
other components of the TGF beta pathways may be
potential therapeutic targets for the treatment of pHGG.
Future studies of the HGG microvascular niche should
focus on the environs of CD105? vessels and their inter-
play with, and possible development from, CD133?
tumour cells.
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